射血分数保留的心力衰竭的生物标志物临床应用研究进展

Clinical Application of Biomarkers for Heart Failure with Preserved Ejection Fraction

射血分数保留的心力衰竭(HFpEF)是一组复杂的临床综合征,患病率逐年上升,但迄今为止关于HFpEF的发病机制仍不明确,在临床诊断和药物治疗方面也存在局限,难以评估患者预后。近年来,随着对心力衰竭的深入研究,越来越多HFpEF相关生物标志物被发现,它们对HFpEF具有潜在的诊断、治疗和预后评估指导价值。现介绍HFpEF相关生物标志物在诊断及预后评估应用中的研究进展。

Heart failure with preserved ejection fraction(HFpEF)is a complex clinical syndrome,and its prevalence is increasing year by year.However,so far,the pathogenesis of HFpEF is still unclear,and there are also limitations in clinical diagnosis and drug treatment,and it is difficult to evaluate the prognosis of patients.In recent years,with the in-depth study of heart failure,more and more HFpEF-related biomarkers have been found,which have potential diagnostic,therapeutic and prognostic evaluation guiding value for HFpEF.This review will introduce the research progress of relevant biomarkers in the diagnosis and prognosis evaluation of HFpEF.